Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In order to establish the response and tolerance to the intraarterial association of cis-platinum and bleomycin, we have treated 38 patients with advanced head and neck cancer with the following dosages: continuous infusion of bleomycin, 20 mg/m2/day on days 1 and 2, and cis-platinum, 100 mg/m2 in a 3-hr infusion on day 3. Each treatment cycle was repeated every 21 days, the duration being conditioned to tolerance and response. All the patients underwent at least one complete series of treatment. The results were as follows: 11 patients (29%) had complete remission, and 22 (58%) had partial remission. No instances were ascertained of local toxicity (stomatitis, dermatitis). Except for 2 patients with reversible facial paralysis and 6 with anemia, no other signs of general toxicity were ascertained. In conclusion, the intraarterial combination of cis-platinum/bleomycin has proved highly effective (87% response) whereas the low index of local and general toxicity renders the drugs suitable for use before surgery and/or radiotherapy.
Auris Nasus Larynx 1985
PMID:Intraarterial association of cis-platinum and bleomycin in head and neck cancer. 242 88

A new anticancer agent, UFT which is a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil in a molar ratio of 1:4 was administered orally at a dose of 600 mg/day every day. Forty-three patients were evaluable. Eight patients achieved a complete response and eight achieved a partial response with an overall response rate of 37.2%. In terms of response by histology, a response rate was 32.4% (11/34) in cases of squamous cell carcinoma and 75% (3/4) in cases of adenocarcinoma. A response rate by primary site was 57.1% in the nose and paranasal sinuses, 50.0% in the oropharynx and 30.0% in the oral cavity. A response rate was 36.1% in patients with prior treatment and 42.9% in patients with no prior treatment, but there was no statistical significance. Eight of 43 patients developed toxic effects. Most of them were mild such as anorexia, nausea, and stomatitis, but in one case of maxillary sinus carcinoma, severe bone marrow suppression was observed. UFT is a considerably effective and useful drug in the treatment of head and neck cancer. It is possible to increase cure rate by examining various usages of UFT.
Auris Nasus Larynx 1985
PMID:Clinical trials on UFT in the treatment of head and neck cancer. 393 86